ZURICH, Switzerland, July 24 /PRNewswire/ -- Solianis' new patents cover the basic technology to monitor changes in the hydration of skin at different depths and to evaluate the impact of cosmetic products: "Device and method for determining at least one characterizing parameter of multilayer body tissue" and "Method and device for characterizing the effect of a skin treatment agent on skin."
This novel technology has been developed on the basis of the Solianis' multisensor approach: it measures various parameters of human skin, e.g. the parameter moisture in different skin depths.
This spin-off application of Solianis' technology offers new and interesting applications not only in the cosmetic industry to improve product development and give advice to customers but also for everybody who wants to track changes in hydration in the human body such as athletes, physicians, suppliers of energy drinks etc.
"We are proud that our technology in addition to its application in diabetes management offers significant progress in other areas. The range of future products is extended and made even more interesting," says Mario Stark, CEO of Solianis.
Solianis Monitoring AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes. Its technology is based on a unique and proprietary multi-sensor technology for monitoring relevant physiological parameters. It was incorporated on May 12, 2005, and is funded by private investors supported by the pioneer fund of the Cantonal Bank of Zürich.
Contact: Mario Stark, CEO, Tel.: +41-44-306-80-40, Mobile: +41-79-542-88-74, E-Mail: email@example.com .